David Pickering, DO
Internal Medicine · Parkersburg, WVNPI 1932412442
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $494,407 of the $599,058 with a category attached, or 82.5%. 33 manufacturers reported payments, led by Lilly USA, LLC at 37.7% of the total. 2025 is the largest year on record at $154,887, 2.6 times the $60,104 reported in 2019. Among internal medicine clinicians in WV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,959 payments — averaging $305.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$226K
- Novo Nordisk$129K
- Corcept Therapeutics$106K
- Boehringer Ingelheim$43K
- Johnson & Johnson$30K
- AstraZeneca$26K
- plus $39K from 27 others
Across 10 payments — averaging $9486.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Mannkind Corporation$95K
What the payments were for
- Consulting fees$8,9151%
- Speaking & faculty fees$494,40783%
- Travel & lodging$63,34811%
- Food & beverage$32,1175%
- Education$1520%
- Gifts$1190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 519 | $225,771 |
| Novo Nordisk | 335 | $129,316 |
| Corcept Therapeutics | 220 | $106,347 |
| Boehringer Ingelheim | 123 | $42,680 |
| Johnson & Johnson(2 entities) | 93 | $30,123 |
| AstraZeneca | 177 | $25,687 |
| Mannkind Corporation | 144 | $18,565 |
| Tandem Diabetes Care, Inc. | 34 | $5,484 |
| Sanofi-aventis U.S. LLC | 48 | $3,362 |
| Medtronic | 35 | $3,118 |
| Valeritas, Inc. | 7 | $1,462 |
| Zealand Pharma US, Inc. | 7 | $1,277 |
| Cequr Corporation | 4 | $1,252 |
| Abbott | 68 | $1,012 |
| Insulet Corporation | 36 | $985 |
| Merck | 41 | $587 |
| Bayer | 10 | $341 |
| Dexcom, Inc. | 13 | $311 |
| Janssen Scientific Affairs, LLC | 2 | $209 |
| Xeris Pharmaceuticals, Inc. | 9 | $206 |
| Kowa Pharmaceuticals America, Inc. | 12 | $204 |
| Melinta Therapeutics, LLC | 1 | $125 |
| Ascensia Diabetes Care US Inc. | 1 | $120 |
| Ironshore Pharmaceuticals Inc. | 1 | $111 |
| Recordati_rare_diseases_inc. | 4 | $74 |
| EUSA Pharma (US) LLC | 4 | $74 |
| BETA Bionics, Inc. | 2 | $64 |
| Sequel Med Tech, LLC | 2 | $48 |
| AbbVie | 2 | $39 |
| Senseonics, Incorporated | 1 | $35 |
| Averitas Pharma Inc. | 2 | $35 |
| Amarin Pharma, Inc. | 1 | $22 |
| Novartis | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$147,145
- Korlym$103,092
- Ozempic$57,868
- JARDIANCE$54,848
- TRULICITY$44,879
- RYBELSUS$35,508
- INVOKANA$28,657
- FARXIGA$22,266
- AFREZZA$11,133
- V-GO$7,585
- Tresiba$7,311
- Xultophy 100/3.6$6,290
- Victoza$5,377
- t-slim insulin pump$4,346
- DISEASE STATE$2,200
- CeQur Simplicity$1,199
- INPEN SMART INSULIN DELIVERY SYSTEM$1,145
- t:slim X2 insulin pump$850
- MINIMED 780G$512
- InPen$500
How this compares
$599,058 in reported general payments places this provider in the 95th percentile of 573 internal medicine providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 621 | $847,251 |
| TrulicityDulaglutide | 453 | $684,942 |
| JardianceEmpagliflozin | 442 | $463,898 |
| FarxigaDapagliflozin Propanediol | 388 | $390,778 |
| AfrezzaInsulin Regular, Human | 64 | $147,943 |
| V-Go 40Sub-Q Insulin Device, 40 Unit | 149 | $105,358 |
| V-Go 30Sub-Q Insulin Device, 30 Unit | 144 | $97,624 |
| MounjaroTirzepatide | 82 | $97,507 |
| Tresiba Flextouch U-200Insulin Degludec | 132 | $93,691 |
| V-Go 20Sub-Q Insulin Device, 20 Unit | 135 | $81,977 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 66 | $72,231 |
| RybelsusSemaglutide | 34 | $57,895 |
| InvokanaCanagliflozin | 53 | $53,533 |
| NovologInsulin Aspart | 190 | $46,459 |
| Humulin R U-500Insulin Regular, Human | 19 | $39,679 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog, Fiasp | $129,316 | $978,247859 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Insulin Lispro | $225,771 | $804,514695 claims |
| Boehringer IngelheimJardiance | $42,680 | $463,898442 claims |
| AstraZenecaFarxiga | $25,687 | $390,778388 claims |
| Mannkind CorporationAfrezza | $18,565 | $147,94364 claims |
| Johnson & JohnsonInvokana | $30,123 | $53,53353 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $3,362 | $9,69213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 573 internal medicine providers in West Virginia.
Other internal medicine in Parkersburg
- Orton ArmstrongParkersburg$9K
- Jennifer LeavittParkersburg$8K
- William TomlinsonParkersburg$7K
- Joan AllmanParkersburg$5K
- William ChapmanCharleston$1.7M
- Govind PatelFairmont$59K
- Bisher MustafaHuntington$28K
- Johny AlencherryMartinsburg$27K
- Ali KhanBuckhannon$21K
- Joseph HashemBerkeley Springs$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.